

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/10/2010; page 1 TMP 045

Suggested Formula	Caffeine Citrate 20 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 631	
----------------------	---	-----	-----------	--

Note: Caffeine Citrate 20 mg/mL is equivalent to Caffeine 10 mg/mL.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Caffeine (anhydrous), USP	0.300	g				
Citric Acid (anhydrous), USP	0.15	g				
Sodium Citrate (dihydrate), USP	0.25	g				
Sterile Water For Injection, USP	24.0	mL)		
Sterile Water For Injection, USP	q.s. to 30.0	mL		7		
Citric Acid 10% solution	As needed					

SPECIAL PREPARATORY CONSIDERATIONS

Suggested Preparatory Guidelines	
Non-Sterile Prepara	tion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 797</i> . Only trained and qualified personnel must prepare this formula.
	All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.
	Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.
	Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.
	Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/10/2010; page 2 TMP 045

Suggested Formula	Caffeine Citrate 20 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 631
----------------------	---	-----	-----------

SUGGESTED PREPARATION (for 30 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Caffeine (anhydrous), USP §	0.300	g			
Citric Acid (anhydrous), USP §	0.15	g			
Sodium Citrate (dihydrate), USP §	0.25	g	®		
Sterile Water For Injection, USP §	24.0	mL			
Sterile Water For Injection, USP §	q.s. to 30.0	mL			
Citric Acid 10% solution §	As needed				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. **Powder-liquid preparation:**

- A. In the given order, sequentially add the following ingredients to the Sterile Water For Injection (24.0 mL *plus* processing error adjustments):
 - -Citric Acid (anhydrous)
 - -Caffeine (anhydrous)
 - -Sodium Citrate (Dihydrate)

Specification: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/10/2010; page 3 TMP 045

Suggested Formula	Caffeine Citrate 20 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 631	
----------------------	---	-----	-----------	--

3. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 2A).
- B. Test the pH of the sample. It should lie between 4.2 and 5.2.
- C. If the pH > 5.2, carefully add, in a dropwise fashion, the Citric Acid 10% solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Citric Acid 10% solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Citric Acid 10% solution.
 - Re-test the pH.
 - 4. Continue to add the Citric Acid 10% solution until the pH of 4.2 to 5.2 is obtained.

IMPORTANT: Do not allow the pH to drop below 4.2.

4. **Filling to volume:**

A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (30.0 mL *plus* processing error adjustments).

Specification: Continuously mix.

End result: Homogeneous liquid-like solution.

5. Filtering and transferring:

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

6. Filter integrity test:

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

7. Sterility testing:

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/10/2010; page 4

Suggested Formula	Caffeine Citrate 20 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 631
----------------------	---	-----	-----------

SUGGESTED PRESENTATION

GGEGTEDTK		MITATION	-		
Estimated Beyond-Use Date		14 days, refrigerated, per USP guidelines.	Packa Requiren		Sterile, tightly closed, unit dose vials.
	1	Use as directed. Do not exceed dose.	d prescribed	5	Discard in the presence of particulate matter.
	2	Keep out of reach of children.		6	Discard container after use.
Auxiliary Labels	3 Keep refrigerated. Do not freeze.		7	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	
	4	Do not use if product changes co	olor.	8	C.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary				nsing container as deemed necessary.
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

REFERENCES

 	ENGEG
1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Caffeine Citrate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1116.
3.	Caffeine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #1636.
4.	Caffeine (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 1741.
5.	Sodium Citrate (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 3572.
6.	USP <797>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 318.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.